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scriptions were adequate in both study periods according to recent guidelines. GPA 
co-prescription with NSAIDs remains greatly suboptimal.
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INDIRECT TREATMENT COMPARISONS OF BIOLOGIC THERAPIES FOR 
RHEUMATOID ARTHRITIS
Alfonso R, Devine B, Sullivan SD
University of Washington, Seattle, WA, USA
OBJECTIVES: To compare the efﬁcacy results of biological therapies for rheumatoid 
arthritis (RA) using indirect treatment comparisons and meta-regression techniques. 
METHODS: We performed a literature search to identify the randomized clinical trials 
(RCTs) of biological therapies for RA. Using these studies we created a network and 
developed two random effects, logistic regression models (6- and 12-months), using 
the ACR-50 as the primary outcome. We chose mean disease duration and mean 
baseline HAQ-DI score as meta-regression covariates, to account for heterogeneity 
between trials, as these have prognostic value in determining the effect of RA treat-
ment. RESULTS: We included 18 RCTs in the 6-month analysis and 10 RCTs in the 
12-month analysis. Eight biologic agents are included in the 6-month analysis and six 
in the 12-month. The results of the 6-month analysis suggest that the eight biologic 
agents are signiﬁcantly more effective than the comparator (p < 0.05): Certulizumab 
(log odds ratio, median = 2.6), rituximab (1.7), adalimumab (1.6), inﬂiximab (1.6), 
etanercept (1.4), golimumab (1.3), abatacept (1.2), and anakinra (1.0). The results 
also indicate that methotrexate (MTX) is signiﬁcantly more effective than placebo 
(0.7). The parameter values for the 12-month analysis are similar, with the effective-
ness of the biologics following the same order, but without golimumab and anakinra. 
CONCLUSIONS: Our results suggest that biologic treatments are more effective than 
MTX or placebo, but they may differ from one another. There are differences in the 
outcomes depending on whether we evaluate the ACR-50 at 6-months or 12-months. 
Biologic agents seem to be more effective with longer disease duration.
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BACKGROUND: Charting across practices for RA patients varies greatly and rarely 
uses formal measures to assess treatment effectiveness outside clinical trials. OBJEC-
TIVES: To develop a tool to assess treatment effectiveness in real-world practice using 
information commonly found in charts. METHODS: From an ongoing chart audit, a 
sample of ten de-identiﬁed charts of RA patients initiating TNF blocker treatment was 
reviewed by four clinical rheumatologists to determine useful variables commonly 
found in charts. National guidelines were reviewed to determine which variables are 
used to assess treatment effectiveness in clinical trials. A scale was created and deﬁned 
for each variable. Criteria to assign an overall outcome change score from baseline 
through follow-up were created. Three additional rheumatologists were added to test 
the scale using 51 additional charts. Each chart was reviewed by two pairs of rheu-
matologists. Sufﬁcient inter-rater reliability could not be achieved due to lack of 
consistent data, so differences in ratings were reconciled by discussion between raters 
and ﬁnal scores were assigned by consensus. If consensus could not be reached, a third 
pair of rheumatologists reviewed the chart and the ﬁnal score was assigned by con-
sensus. RESULTS: Key available variables identiﬁed were: patient joint pain, synovitis, 
patient global assessment, lab markers (CRP and ESR), patient-reported outcomes 
surveys, and other (fatigue, physician global assessment, morning stiffness, and radio-
graphic information). All variables were scored much worse, worse, no change, better, 
and much better from the baseline to the follow-up visit. An overall outcome change 
score was assigned using the same scale. Missing data were considered no change. 
Clinical judgment was an essential component to the score. Agreement was good 
between pairs of raters; 53% of initial scores matched and 39% were within one 
category. CONCLUSIONS: A rating scale can be applied by experienced clinicians 
and used for comparative effectiveness research.
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OPERATIVE RISK OF STAGED BILATERAL KNEE REPLACEMENT IS 
UNDER-ESTIMATED IN RETROSPECTIVE STUDIES
Kim S, Meehan JP, White RH
University of California, Davis, Sacramento, CA, USA
OBJECTIVES: Surgical options for patients with symptomatic bilateral knee osteoar-
thritis are 1) simultaneous bilateral total knee arthroplasty (BTKA) under one anes-
thesia and 2) staged total knee arthroplasty (STKA) with two distinct operations 
separated by a few days up to one year. A number of studies have compared post-
operative complications after BTKA versus STKA by simply collecting and then 
contrasting outcomes collected retrospectively. However, this methodology is biased 
because it fails to account for the patients who had STKA planned but who never 
completed the second stage because they died or developed a serious post-operative 
complication after the ﬁrst operation, leading to cancellation of the second STKA. The 
purpose of this study was to demonstrate the misclassiﬁcation bias associated with 
simply comparing operative outcomes after BTKA versus STKA. METHODS: To 
demonstrate the bias, a mathematical derivation and graphical presentation were 
developed. RESULTS: First, we mathematically demonstrated that the observed pro-
portion of complication (Pobserved) in patients who completed both STKA operations 
underestimates the true proportion of complication (Ptrue). Second, we graphically 
demonstrated that STKA always appears to be safer than BTKA even if when the 
proportion of post-operative complications observed is held constant. When data were 
simulated using a true odds ratio of 1, the observed odds ratio ranged from 0.899 to 
0.557 for various combination of other probabilities.CONCLUSIONS: Most pub-
lished studies have reported that post-operative complications are lower for STKA 
compared with BTKA. However, our analysis indicates that any conclusions based 
simply on retrospective analysis of subjects who successfully completed STKA is biased 
because it includes only cases that recovered after the ﬁrst operation rather than all 
of the patients that had STKA planned. Absent a prospective study, the only fair and 
unbiased comparison of post-operative complications between STKA and BTKA 
requires adjustments to account for this bias.
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OBJECTIVES: To map the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) onto the EQ-5D utility index in patients with knee osteoarthritis 
(OA). METHODS: A consecutive sample of patients (n = 258) with diagnosed knee 
OA completed both the WOMAC and the EQ-5D. Regression models with ordinary 
least squares (OLS) or the censored least absolute deviations (CLAD) as the estimator 
were used to establish the mapping function. The WOMAC was represented as 
explanatory variables in four ways: (a) total score; (b) domain scores (i.e., pain, stiff-
ness, and physical function), (c) domain scores plus pairwise interaction terms to 
account for possible nonlinearities; and (d) individual item scores. Goodness-of-ﬁt 
criteria included mean absolute error (MAE, the primary criterion) and root mean 
squared error (RMSE) obtained using an iterative random sampling procedure. Predic-
tion precision was evaluated at individual patient level and at the group level. 
RESULTS: The model using OLS estimator and WOMAC domain scores as explana-
tory variables had the best ﬁt and was chosen as the preferred mapping model. The 
prediction error at individual level exceeded the maximal tolerance value (i.e. the 
minimally important difference of EQ-5D) in about 16% of patients. At group level, 
the width of 95% CI of prediction errors varied from 0.0176 at a sample size of 400 
to 0.0359 at a sample size of 100. CONCLUSIONS: EQ-5D scores can be predicted 
using WOMAC domain scores with an acceptable precision at both the individual and 
group levels in patients with mild to moderate knee OA.
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OBJECTIVES: Despite using fully adjudicated claims, analyzing biologics treatment 
patterns requires reliable data cleaning and imputation methods for both pharmacy 
and professional claims. Self-injected agents with longer dosing intervals present 
unique challenges for data analysis. We developed methods to improve interpretability 
while minimizing data loss using TNF blocker claims. METHODS: A large health 
plan claims database was used to obtain 3,725 Psoriasis and/or Psoriatic Arthritis 
subjects initiating adalimumab (ADL) or etanercept (ETN) between January 1, 2003 
and March 31, 2009; and were enrolled for 360 days pre- and ≥180 days post-index 
(ﬁrst TNF claim). Patients were excluded if they had other inﬂammatory disorders 
pre- or post-index or received any biologic pre-index. We reviewed patients’ drug 
dispensing histories, established acceptable ranges for key claim values, and developed 
imputation rules that leveraged allowed reimbursements and dispensed quantities 
when other values were discrepant or missing. For professional claims, we divided 
total doses across weeks between ﬁlls to obtain average weekly dose. RESULTS: A 
total of 89.2% of 46,206 ETN and 94.6% of the 3,470 ADL claims were from 
pharmacies. 9.7% subjects with ≤0 reimbursed amounts on index were excluded, as 
were 0.9% with extreme quantity values (>48/ >16 for ETN pharmacy/professional 
claims, >12 for ADL) and 1.0% patients with extreme weekly dose values in any claim 
(>250 mg for ETN, >200 mg for ADL). 8.8% subjects had >1 same-day claims, which 
were sorted in descending order of charge, allowed, and paid, with the top claim 
retained. After these steps, 3065 (82.3%) subjects remained in the cohort. CONCLU-
SIONS: Analyzing TNF blocker treatment patterns from claims requires adjustments 
for weekly dosing schedules and for professional claims that reﬂect dispensing of 
supplies for home injection. However, the limited dosing schedules for ADL and ETN 
allow for data cleaning strategies that address these challenges while retaining the vast 
majority of data.
